(RTTNews) - Ionis Pharmaceuticals Inc. (IONS) announced that GSK presented positive results from an interim analysis of the Phase 2b B-Clear clinical study of bepirovirsen (formerly IONIS-HBVRx), an ...
1dOpinion
The Journey To Hepatitis B Elimination Through Innovation, Early Testing, And Scientific Discovery
As hepatitis B research progresses, achieving higher functional cure rates is becoming more feasible. It is vital that ...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it will be presenting new data from its ongoing Phase 2 SOLSTICE and MARCH trials evaluating the potential ...
Hepatitis B viral load is the amount of hepatitis B virus (HBV) found in a person’s bloodstream. Hepatitis B is a viral infection that can pass from person to person through bodily fluids. It ...
Altimmune has been beaten by hepatitis B. The drug candidate, which the company was preparing for partnering, failed to meet the bar for further development in a phase 2 study, prompting the biotech ...
SAN FRANCISCO, Sept. 18, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a clinical-stage biotechnology company advancing targeted ...
Three scenarios can occur after spontaneous seroconversion from HBeAg to anti-HBe: Most individuals go into the inactive hepatitis B phase ("inactive carrier"), characterized by normalization of serum ...
An ad hoc committee under the auspices of the Institute of Medicine will be convened to complete a two phase study on hepatitis B and C elimination. The IOM will conduct a literature review and ...
NEW YORK and VIENNA, Austria, May 09, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus ...
-- After the pre-Phase III clinical trial meeting with Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) in June 2022, the pathway to the registration, ...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 ...
– Initial SOLSTICE data suggests the potential of VIR-3434 + VIR-2218 to address the unmet need for a highly efficacious hepatitis delta therapy – – New MARCH Part B data demonstrate that VIR-3434 may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback